Paris (France), Houston (USA), San Francisco (USA) — November 25, 2024 — Lauxera Capital Partners announces the acquisition of Galen Data, a leading provider of secure, cloud-based connectivity solutions for medical devices. This transaction follows Lauxera’s 2022 acquisition of Matrix Requirements, a leading ALM and eQMS software solution for medical device R&D and Quality teams.  This strategic transaction brings together two industry leaders serving the same end-customers with highly complementary products. “The Galen team has built an exceptional product providing medical device companies a cost-effective, compliant, and secure solution for medical device cloud connectivity. Innovation in Medtech is no longer only about better electronic, metal, and plastic designs. Galen empowers Medtech companies to improve care by leveraging the data generated by their medical devices. “We are excited to work hand in hand with management to strengthen the company’s global commercial engine,” said Samuel Levy, Founding Partner, Lauxera Capital Partners.   For Galen Data, this acquisition represents an exciting new chapter with expanded financial resources and a broader, global team.   “We’re incredibly excited to join forces with Lauxera Capital Partners and Matrix Requirements. Their strategic insights and global reach will allow us to accelerate growth into new markets, expand our services, and continue delivering cutting-edge solutions to the medical device industry. This partnership empowers us to take our business to the next level and better serve our clients while pushing forward the innovation that’s at the core of everything we do,” Chris DuPont, CEO, Galen Data.  "This acquisition is an important step towards our vision to provide turnkey vertically-integrated software solutions to address pain points faced by medical devices companies. I am thrilled to welcome Galen’s team.” added Laurent Grandidier, Executive Chairman of the Board.  Lauxera Capital Partners was advised by Goodwin Proctor on legal and tax matters.  About Lauxera Capital Partners  Founded in January 2020, Lauxera Capital Partners is an independent asset management company based in France (Paris) and in the United States (San Francisco). Lauxera is a healthcare specialist investor working to promote the growth of European Healthtech companies. Its first fund, Lauxera Growth I, gathered 262m€ of capital from investors and had invested in 12 fast-growing Healthtech businesses in France, the UK, Germany, Sweden, Denmark and the United States. Led by a team of life sciences entrepreneurs and professional healthcare investors with more than 50 years’ experience, Lauxera aims to support the international commercial expansion of Europe's most promising Healthtech innovations. Lauxera’s highly focused investment approach, its intimacy with the US healthcare ecosystem, its distinctive understanding of innovation trends across Europe and the operating and investment experience of its partners enables Lauxera to be a strong value-add partner for its investee companies.  About Galen Data  Galen Data provides a secure, cloud-based platform designed to connect medical devices to the cloud, allowing for real-time data collection, storage, and analysis. Galen’s platform is compliant with key medical device industry standards, including FDA, HIPAA, GDPR, and CE Marking, which helps medical device companies accelerate time-to-market while ensuring regulatory compliance. Galen Data’s solution simplifies the process of managing connected medical devices by offering a secure and scalable infrastructure tailored to the needs of healthcare technology providers.  Galen Data is an ISO 13485:2016 certified company and is HITRUST r2 Certified on AWS. 

The University of Houston (UH) and Baylor College of Medicine (BCM) have been awarded a $44.2 million grant from the National Center for Advancing Translational Research. This funding will support the establishment of a regional hub dedicated to advancing clinical and translational research.  Dubbed the Consortium for Translational and Precision Health (CTPH), the new hub will enhance collaboration between the two institutions and other clinical and research groups within the Texas Medical Center. The CTPH aims to expedite the translation of new technologies and discoveries into patient care and real-world impact, provide funding and resources to accelerate pilot projects and research initiatives and connect investigators with local healthcare organizations and government agencies that are dedicated to healthcare, clinical research and policy.  “Research is the engine empowering health care’s life-changing advancements,” said UH President Renu Khator, in a release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”  The hub will be led by BCM’s Christopher Amos, professor and director of the Institute for Clinical and Translational Research, and Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology, alongside UH’s Dr. Bettina M. Beech, clinical professor of population health and chief population health officer.  “The CTPH is a partnership that draws on strengths of both institutions, creating a rich multidisciplinary environment. It will act as the vehicle to enhance the infrastructure and resources needed to effectively conduct research and implement solutions to advance healthcare,” said Dr. Carolyn Smith, interim senior vice president and dean of research at BCM. “It will help implement and create ongoing core research activities that will support the clinical translational science at both institutions.”  This strategic partnership comes at a time when local institutions are intensifying efforts to advance critical research that will deliver vital healthcare solutions. The University of Texas MD Anderson Cancer Center and Rice University recently announced a collaboration to advance fundamental and translational cancer research and develop life-saving technologies. Additionally, a research initiative led by Rice University, in collaboration with MD Anderson, received an $18 million grant to improve tumor removal technology for breast, head and neck cancer.  Learn more about Houston’s Life Sciences industry.